» Articles » PMID: 32531019

Respiratory Syncytial Virus-Associated Hospitalizations Among Adults With Chronic Medical Conditions

Overview
Journal Clin Infect Dis
Date 2020 Jun 13
PMID 32531019
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In contrast with respiratory disease caused by influenza, information on the risk of respiratory syncytial virus (RSV) disease among adults with chronic medical conditions (CMCs) is limited.

Methods: We linked population-based surveillance of acute respiratory illness hospitalizations to national administrative data to estimate seasonal RSV hospitalization rates among adults aged 18-80 years with the following preexisting CMCs: chronic obstructive pulmonary disease (COPD), asthma, congestive heart failure (CHF), coronary artery disease (CAD), cerebrovascular accidents (CVA), diabetes mellitus (DM), and end-stage renal disease (ESRD). Age- and ethnicity-adjusted rates stratified by age group were estimated.

Results: Among 883 999 adult residents aged 18-80 years, 281 RSV-positive hospitalizations were detected during 2012-2015 winter seasons. Across all ages, RSV hospitalization rates were significantly higher among adults with COPD, asthma, CHF, and CAD compared with those without each corresponding condition. RSV hospitalization rates were significantly higher among adults with ESRD aged 50-64 years and adults with DM aged 18-49 years and 65-80 years compared with adults in each age group without these conditions. No increased risk was seen for adults with CVA. The CMC with the highest risk of RSV hospitalization was CHF (incidence rate ratio [IRR] range, 4.6-36.5 across age strata) and COPD (IRR range, 9.6-9.7). Among RSV-positive adults, CHF and COPD were independently associated with increased length of hospital stay.

Conclusions: Adults with specific CMCs are at increased risk of RSV hospitalizations. Age affects this relationship for some CMCs. Such populations maybe relevant for future RSV prevention strategies.

Citing Articles

Targeting Non-Eosinophilic Immunological Pathways in COPD and AECOPD: Current Insights and Therapeutic Strategies.

Razia D, Gao C, Wang C, An Y, Wang F, Liu L Int J Chron Obstruct Pulmon Dis. 2025; 20:511-532.

PMID: 40066199 PMC: 11892741. DOI: 10.2147/COPD.S506616.


Burden of Respiratory Syncytial Virus Disease in Adults with Asthma and Chronic Obstructive Pulmonary Disease: A Systematic Literature Review.

Penders Y, Brusselle G, Falsey A, Rohde G, Betancur E, Guardado M Curr Allergy Asthma Rep. 2025; 25(1):14.

PMID: 39994162 PMC: 11850418. DOI: 10.1007/s11882-025-01194-w.


Prevalence of Respiratory Syncytial Virus Infection in Hospitalized COPD Patients in Spain Between 2018-2022.

Gomez-Garcia R, de-Miguel-Diez J, Lopez-de-Andres A, Hernandez-Barrera V, Jimenez-Sierra A, Cuadrado-Corrales N Diseases. 2025; 13(1).

PMID: 39851487 PMC: 11764113. DOI: 10.3390/diseases13010023.


The Impact of Vaccination on COVID-19, Influenza, and Respiratory Syncytial Virus-Related Outcomes: A Narrative Review.

Debbag R, Rudin D, Ceddia F, Watkins J Infect Dis Ther. 2024; 14(Suppl 1):63-97.

PMID: 39739199 PMC: 11724835. DOI: 10.1007/s40121-024-01079-x.


A Narrative Review of Key Risk Factors for Severe Illness Following SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus Infection.

Branche A, Ramesh M, Francis B Infect Dis Ther. 2024; 14(Suppl 1):39-61.

PMID: 39739198 PMC: 11724830. DOI: 10.1007/s40121-024-01081-3.